@article {1405411,
	title = {PR1P ameliorates neurodegeneration through activation of VEGF signaling pathway and remodeling of the extracellular environment},
	journal = {Neuropharmacology},
	volume = {148},
	year = {2019},
	month = {2019 Apr},
	pages = {96-106},
	abstract = {Neurodegenerative diseases affect millions of people worldwide. Optic neuropathies are the most commonly occurring neurodegenerative diseases, characterized by progressive retinal ganglion cell (RGC) degeneration. We recently reported that Prominin-1, a protein found on the surface of stem cells, interacts with VEGF and enhances its activity. VEGF is known to have various protective roles in the nervous system. Subsequently, we have developed a 12-mer peptide derived from Prominin-1, named PR1P, and investigated its effects on neuronal survival of damaged RGCs in a rat model of optic nerve crush (ONC). PR1P prevented RGC apoptosis resulting in improvement of retinal function in the rat ONC model. PR1P treatment significantly increased phosphorylation of ERK and AKT and expression its downstream proteins c-fos and Egr-1 in the retina. Additionally, PR1P beneficially increased the MMP-9/TIMP-1 ratio and promoted glial activation in the retina of ONC rats. Thus, PR1P displayed neuroprotective effects through enhanced VEGF-driven neuronal survival and reconstruction of the extracellular environment in ONC model. Our data indicate that PR1P may be a promising new clinical candidate for the treatment of neurodegenerative diseases.},
	issn = {1873-7064},
	doi = {10.1016/j.neuropharm.2018.12.029},
	author = {Chi, Zai-Long and Adini, Avner and Birsner, Amy E and Bazinet, Lauren and Akula, James D and D{\textquoteright}Amato, Robert J}
}
